Previous 10 | Next 10 |
Summary BioVie’s NE3107 has now shown improvement of cognition and function on different Alzheimer’s rating scales, supported by biomarkers and neuroimaging data. The data just released from a Phase 2 placebo-controlled trial in Parkinson’s disease with the same dru...
Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. A...
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced reg...
AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agree...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In today’s mixed session, there are plenty of stocks making big moves. Among the biggest movers in this afternoon’s session is Cassava Sciences (NASDAQ: SAVA ). Currently, SAVA stock has sur...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: beeboys / Shutterstock Investors are wondering if the stock market is open on Election Day this year and we have the answer! Traders that were hoping for a day off to head to the polls are out of luck. Elect...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in the spotlight following the company’s third-quarter earnings and a stark warning to short sellers . During Q3, the company reported a net loss of $20.3...
Cassava Sciences press release ( NASDAQ: SAVA ): Q3 GAAP EPS of -$0.51 beats by $0.08 . Net cash use for operations for full-year 2022 is expected to be approximately $80 to $90 million, consistent with previous guidance. Cash and cash equivalents were $174.7 milli...
– $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzheimer’s Disease Expected – AUSTIN, Texas, Nov. 07, 2022 (GLOB...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...